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The vertebrate immune system must be 
capable of protecting the host from patho-
gens while remaining unresponsive to 
self. The dependence of adaptive immune 
responses on innate or pro-inflammatory 
signals may be a consequence of evolution, 
as such signals usually accompany infec-
tions and thus indicate a perturbation of 
immune homeostasis. Innate signals result 
in the activation and maturation of den-
dritic cells (DCs), which is a prerequisite 
for the induction of protective immu-
nity.1 In contrast, immature DCs promote 
peripheral T-cell tolerance through a vari-
ety of mechanisms, including signals that 
are transduced via PD-1 and CTLA-4.1
While malignant cells can be efficiently 
recognized by the immune system, protec-
tive immunity is most often insufficient 
in cancer patients. Besides local immu-
nosuppression and immunoediting,2 we 
think that an inadequate DC maturation 
contributes to impaired immunity in the 
context of cancer. The observation that 
the frequency of tumor-infiltrating regu-
latory T cells (Tregs) correlates with poor 
prognosis in many different cancer types2 
may be partially explained by the capac-
ity of Tregs to keep DCs in an immature 
state.3 Accordingly, DC activation with-
out further manipulations has been shown 
to result in tumor control in preclinical 
models.4,5 The remarkable clinical efficacy 
Radiotherapy supports  
protective tumor-specific immunity
Anurag Gupta,† Anu sharma,† Lotta von Boehmer, Laura surace, Alexander Knuth and Maries van den Broek*
Department of Oncology; university hospital Zurich; Zurich, switzerland
†these authors contributed equally to this work.
Keywords: radiotherapy, mouse, dendritic cells, human, CD8 T cells
*Correspondence to: Maries van den Broek; Email: maries@van-den-broek.ch
Submitted: 07/06/12; Accepted: 07/13/12
http://dx.doi.org/10.4161/onci.21478
of Coley’s toxin—a mixture of heat-killed 
Streptococcus pyogenes and Serratia marces-
cens that was used by William Coley in the 
19th century to treat cancer patients6—
may also result from the activation of 
DCs, which obviously was not appreciated 
at that time.
Radiotherapy and chemotherapy are 
standard treatments for cancer and both 
have been considered as immunosuppres-
sive measures for a long time. However, 
a growing body of evidence suggests that 
chemotherapy, at least in some instances, 
actually supports tumor-specific immunity 
and that DC activation is a crucial aspect 
herein.5,7 Also radiotherapy, especially 
when administered in limited fractions 
of high dose, positively influences tumor-
specific immunity. For example, radio-
therapy results in local production of Type 
I interferon,8 which enhances the cross-
presentation of tumor-derived antigens 
by DCs and improves qualitative as well 
as quantitative aspects of tumor-specific 
immunity.9 We are currently investigat-
ing whether tumor-associated plasmacy-
toid dendritic cells (pDCs) are a source of 
radiation-induced Type I interferon. We 
have found that the therapeutic efficacy 
of a single dose of X-rays (10 Gy) crucially 
depends on the presence of CD8+ T cells 
and of DCs during and/or immediately 
after radiotherapy.5 Importantly, this was 
the case for multiple transplantable synge-
neic tumors in at least two different genetic 
backgrounds, suggesting a rather general 
mechanism. In contrast, macrophages or 
CD4+ T cells were dispensable for the ther-
apeutic efficacy of radiotherapy. Moreover, 
we found that local high-dose radiother-
apy activates tumor-associated DCs, in a 
fashion that is independent of MYD88, 
NALP3 or DNGR1 (CLEC9A) (unpub-
lished observations). In contrast to what 
has been described for particular types of 
chemotherapy,7 radiotherapy apparently 
does not induce the upregulation of the 
non-histone chromatin binding protein 
HMGB1 (unpublished observations). 
This suggests that the activation of DCs 
induced by radiotherapy and chemother-
apy involves different signaling pathways. 
Maturation rather than the mere pres-
ence of tumor-associated DCs is a crucial 
aspect of radiotherapy, because blockade 
of CD70—an important co-stimulatory 
molecule for the priming of protective 
CD8+ T cell-dependent immunity—com-
pletely abolished the therapeutic efficacy of 
radiotherapy.5 Based on our data, we think 
that radiotherapy does not necessarily pro-
mote the infiltration of tumor-specific T 
cells, but supports their proliferation and/
or survival within the tumor. In addi-
tion, tumor-specific CD8+ T cells seem 
to better maintain their effector function 
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radiotherapy induces the upregulation 
of MHC Class I molecules and CTAs, 
which makes cancer cells better targets 
for the immune system. Third, radio-
therapy disturbs immune homeostasis 
in a way that results in DC maturation. 
Fourth, radiotherapy supports the sur-
vival, proliferation and maintenance of 
effector functions of tumor-infiltrating 
T cells, resulting in a qualitatively and 
quantitatively improved T-cell infiltrate. 
We propose that combining radiotherapy 
with immunostimulation may result in 
synergistic anticancer effects.
found a significant decrease of molecules 
involved in immunosuppression such as 
interleukin-10, transforming growth fac-
tor β and PD-L1 (Sharma A et al., manu-
script in preparation).
In summary, we think that radiother-
apy supports tumor-specific immunity at 
both tumor-intrinsic and tumor-extrinsic 
levels (Fig. 1). First, radiotherapy induces 
the death of tumor cells, resulting in the 
release of tumor-associated antigens and 
presumably in their cross-presentation by 
DCs, which is further promoted by radi-
ation-induced Type I interferon. Second, 
within irradiated, as compared with non-
irradiated, tumors. Whether other solu-
ble factors or cell populations other than 
activated DCs contribute to the increased 
number and function of tumor-infiltrating 
T cells after radiotherapy is the subject of 
ongoing investigation.
Reits et al. described in 2006 that 
the γ irradiation of cancer cells leads to 
an increased expression of MHC Class I 
molecules in an mTOR-dependent fash-
ion. This observation prompted us to 
investigate whether also cancer-testis anti-
gens (CTAs), a particular class of tumor-
associated antigens that are often targeted 
spontaneously by the immune system in 
cancer patients, are upregulated upon γ 
irradiation. Indeed, we found that irradia-
tion upregulates the expression of MHC 
Class I molecules and various CTAs 
(including some cases of de novo expres-
sion) in cancer cell lines and fresh human 
tumor material ex vivo, in xenografted 
human cell lines in vivo and in biopsies 
from sarcoma patients.10 Obviously, the 
upregulation of both MHC Class I mol-
ecules and CTAs makes cancer cells more 
visible to cytotoxic T cells, which pre-
sumably contributes to the therapeutic 
efficacy of radiotherapy. Retrospective 
analyses of a cohort of sarcoma patients, 
from whom paired biopsies were collected 
before and after radiotherapy, showed a 
striking impact of radiotherapy on mul-
tiple immune parameters within the 
tumor. For example, we found a consis-
tent increase of immune effector cells and 
molecules including CD8+ cells, perforin 
and interferon γ. Along similar lines, we 
Figure 1. radiotherapy supports tumor-specific immunity at multiple tumor-intrinsic and tumor-
extrinsic levels. radiotherapy (1) induces the death of tumor cells, resulting in the release of 
tumor-associated antigens and presumably in their cross-presentation by DCs, which is further 
promoted by radiation-induced type I interferon; (2) induces the upregulation of MhC Class I 
molecules and CtAs, which makes cancer cells better targets for the immune system; (3) disturbs 
immune homeostasis in a way that results in DC maturation; and (4) supports the survival, prolif-
eration and maintenance of effector functions of tumor-infiltrating t cells, resulting in a qualita-
tively and quantitatively improved t-cell infiltrate.
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